Making The Asia-Pacific Region A Destination Of Choice For Oncology Clinical Trials

Over the past decade, the Asia-Pacific (APAC) region has seen the most robust growth in oncology clinical trial activity, with a 138 percent increase over the period from 2010 to 2020.

With our global footprint, we have a meaningful presence and strong capabilities in the APAC region, including extensive clinical trial experience, strong local relationships, and a deep understanding of regulatory requirements and cultural nuances. With our focus on biotech and specialty pharma, we are also well-equipped to help sponsors in the APAC region globalize their trials to the U.S. and other Western countries.

In this white paper, we explore the growth of oncology clinical trials in APAC countries and discuss strategies to support global study success in this dynamic and complex region of the world.